Hydrogenology
Hydrogenology editorial study record

A Novel Therapy for Cisplatin-Induced Allodynia and Dysfunctional and Emotional Impairments in Male and Female Mice

Martínez-Martel I, Pol O · Antioxidants (Basel). 2023;12(12):2063.

PreclinicalH₂-rich waterPublished 2023
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled sex-stratified mouse chemotherapy-toxicity experiment

Research topic

Musculoskeletal and pain research

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Male and female C57BL/6J mice receiving cisplatin

Sample

Behavioral groups n=8; molecular analyses n=3 samples/group

Duration

30 days

Intervention

Prophylactic hydrogen-rich drinking water for 30 consecutive days

Hydrogen form

H₂ dissolved in drinking water — H₂ only, not Brown’s gas and not inhalation.

H₂ specification

Numeric H₂ concentration was not identified in the extracted full-text passages.

H₂ flow

Not applicable — oral water, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

Cisplatin- and vehicle-treated mice receiving ordinary water

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Mechanical and cold allodynia, grip strength, body weight, anxiety- and depressive-like behavior, inflammation and oxidative-stress proteins

Reported result

The article reports prevention of pain-like, functional and emotional changes in both sexes and lower selected inflammatory or oxidative-stress signals.

Results-extraction completeness

Behavioral, sex-stratified and molecular results checked in the open-access full text; numeric H₂ concentration remains to be confirmed.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Mouse model, prophylactic rather than therapeutic design, small molecular samples and many outcomes. It does not establish prevention of cisplatin neuropathy in people.

Applies directly to

Male and female mice receiving cisplatin, not cancer patients.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 38136183 · DOI: 10.3390/antiox12122063

Publisher access

Open-access full text is available through PMC.

Extraction basis

Open-access PMC full text and PubMed record.

Record revision

2026-08-10